15.05.2012 - F-Star's management has been lifted and replaced by a troika of new leaders.
Cambridge - A press note issued by Austrian-British F-Star GmbH on 14 May names the new personnel. Following Keith Fitz-Gerald as CEO is John Haurum who had been CSO of the Danish biotechnology company Symphogen A/S. Also quickly appointed: Jane Dancer and Sharon Grimster. Dancer was previously employed at Cellzome Ltd. At F-Star she becomes Chief Operating Officer (COO). Grimster, formerly employed at Antisoma plc, has been appointed Vice President of Development.
Clearing the management board so vigorously is indeed a surprise, even with the knowledge that the company - a leader in the development of bispecific antibodies - has had a hard time after moving all research operations from Vienna to Cambridge leaving the parent company in Austria. The Supervisory Board did not forget to mention Kevin FitzGerald and thanked him for "his significant contribution in bringing F-star to its current stage of development". He started as the company's CEO in May 2009. Within this three years, the start-up saved €23m using venture financing. He also arranged major alliances with Boehringer Ingelheim and Merck Serono.
With its proprietary technology, F-star produces antibody fragments called Fcabs, which have full antibody capabilities but are believed to have a better biological profile because of their small size. Additionally Fcabs may offer IP advantages in many cases by lacking variable regions, which may be claimed by third party antibody patents. This seems to attract pharma companies. In November 2010, F-star allied with Germany's Boehringer Ingelheim and in September 2011 with Merck Serono.
28.01.2015 EMA recommends suspending around 750 generic medicines marketed throughout the world after India’s GVK Biosciences is accused of faking bioequivalence studies. Meds considered critically important for patients will remain available.
20.01.2015 Ebola research projects are set to receive €215m in funding from the European Commission’s IMI2 Ebola+ programme. Among the project partners are vaccine developers Glaxosmithkline, Johnson&Johnson and Merck.
13.01.2015 Shire beefs up its rare disease portfolio after acquiring NPS Pharma with the aim of becoming a leading biotech in a US$5.2bn deal. Part of the deal is the US biotech's lead portfolio of gastrointestinal and hormone replacement therapies.
09.01.2015 The excitement surrounding CRISPR genome editing shows no sign of abating. This month, Novartis and US biotech Intellia Therapeutics became the first ever biotech-pharma collaboration to use the groundbreaking technology.